Literature DB >> 2953861

Bromocriptine-induced locomotor stimulation in mice is modulated by dopamine D-1 receptors.

D M Jackson, M Hashizume.   

Abstract

Mice were pretreated with reserpine plus alpha-methyl-p-tyrosine (10 mg/kg plus 200 mg/kg). One hour later they were administered the selective dopamine D-2 agonist bromocriptine or vehicle. Three hours after the bromocriptine, mice were challenged with the selective D-1 agonist SKF 38393, and locomotor activity was measured each 5 min for three hours. Neither bromocriptine nor SKF 38393 produced significant stimulation. The combination, however, produced a dose-dependent and coordinated increase in activity. If the bromocriptine was given only one hour before the SKF 38393 challenge (i.e., three hours after the reserpine plus alpha-methyl-p-tyrosine), no interaction was seen. In naive mice, when SKF 38393 and bromocriptine were administered together, the locomotor response to bromocriptine was quantitatively and qualitatively altered. The initial depressant response to bromocriptine was shortened, producing a more rapid onset of the stimulant response. In one experiment, the maximal activity induced by bromocriptine was increased by SKF 38393. The ability of SKF 38393 to alter the locomotor stimulant effect of bromocriptine in naive mice was blocked by their pretreatment with the selective D-1 antagonist, SCH 23390. The data indicate that the locomotor stimulant effects of bromocriptine are modulated by D1 receptors.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2953861     DOI: 10.1007/bf01244104

Source DB:  PubMed          Journal:  J Neural Transm            Impact factor:   3.575


  37 in total

Review 1.  Multiple receptors for dopamine.

Authors:  J W Kebabian; D B Calne
Journal:  Nature       Date:  1979-01-11       Impact factor: 49.962

2.  The roles of presynaptic function and hepatic drug metabolism in the hypothermic actions of two novel dopaminergic agonists.

Authors:  E K Silbergeld; H Adler; S Kennedy; D B Calne
Journal:  J Pharm Pharmacol       Date:  1977-10       Impact factor: 3.765

Review 3.  Ergot drugs and central monoaminergic mechanisms: a histochemical, biochemical and behavioral analysis.

Authors:  K Fuxe; B B Fredholm; S O Ogren; L F Agnati; T Hökfelt; J A Gustafsson
Journal:  Fed Proc       Date:  1978-06

Review 4.  Pharmacological and biochemical evidence for the dopamine agonistic effect of bromocriptine.

Authors:  K Fuxe; B B Fredholm; S O Ogren; L F Agnati; T Hökfelt; J A Gustafsson
Journal:  Acta Endocrinol Suppl (Copenh)       Date:  1978

5.  Differences in the dopaminergic effects of the ergot derivatives bromocriptine, lisuride and d-LSD as compared with apomorphine.

Authors:  R Horowski
Journal:  Eur J Pharmacol       Date:  1978-09-15       Impact factor: 4.432

6.  Effect of haloperidol pre- and post-treatment on the ability of pergolide and bromocriptine to antagonize the gamma-butyrolactone-induced increase in brain dopamine in rats.

Authors:  R W Fuller; K W Perry
Journal:  Biochem Pharmacol       Date:  1982-06-15       Impact factor: 5.858

7.  The mesolimbic nucleus accumbens is critically involved with the mediation of the motor inhibitory and facilitatory effects of dopamine agonists on mouse spontaneous climbing behaviour.

Authors:  B Costall; J F Eniojukan; R J Naylor
Journal:  Eur J Pharmacol       Date:  1983-12-23       Impact factor: 4.432

8.  Bromocriptine enhances the behavioural effects of apomorphine and dopamine after systemic or intracerebral injection in rats.

Authors:  O F Jenkins; D M Jackson
Journal:  Neuropharmacology       Date:  1986-11       Impact factor: 5.250

9.  Bromocriptine potentiates the behavioural effects of directly and indirectly acting dopamine receptor agonists in mice.

Authors:  O F Jenkins; D M Jackson
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1985-10       Impact factor: 3.000

10.  The central effects of a novel dopamine agonist.

Authors:  P E Setler; H M Sarau; C L Zirkle; H L Saunders
Journal:  Eur J Pharmacol       Date:  1978-08-15       Impact factor: 4.432

View more
  6 in total

1.  Role of D-1 and D-2 receptors in apomorphine-induced pecking in chicks.

Authors:  M R Zarrindast; R Amin
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

2.  Locomotor-activating effects of the D2 agonist bromocriptine show environment-specific sensitization following repeated injections.

Authors:  D C Hoffman; R A Wise
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

3.  Dopamine D2 agonist-induced behavioural depression is reversed by dopamine D1 agonists.

Authors:  D M Jackson; S B Ross; S R Edwards
Journal:  J Neural Transm       Date:  1989       Impact factor: 3.575

Review 4.  The motor effects of bromocriptine--a review.

Authors:  D M Jackson; O F Jenkins; S B Ross
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

5.  Further studies on the interaction between bromocriptine and SKF38393 in reserpine and alpha methyl-para-tyrosine-treated mice.

Authors:  D M Jackson; S B Ross; M Hashizume
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

6.  Effects of acute administration of DA agonists on locomotor activity: MPTP versus neonatal intracerebroventricular 6-OHDA treatment.

Authors:  Trevor Archer; Tomas Palomo; Robert McArthur; Anders Fredriksson
Journal:  Neurotox Res       Date:  2003       Impact factor: 3.978

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.